Fla. Admin. Code R. 64D-3.029
Practitioner Reporting | Laboratory Reporting | |||||||||||
Reportable Diseases or Conditions | Timeframes | Evidence of current or recent infection with etiological agents and all associated testing results performed should be reported (e.g. species, serogroup, serotype, and antimicrobial susceptibility *2 results) | Timeframes | |||||||||
Suspect Immediately | Immediately | Next Business Day | Other | Submit isolates or specimens for confirmation *1 | Suspect Immediately | Immediately | Next Business Day | Other | ||||
Any case, cluster of cases, outbreak, or exposure to an infectious or non-infectious disease, condition, or agent found in the general community or any defined setting such as a hospital, school or other institution, not listed in this rule that is of urgent public health significance. This includes human cases, clusters, or outbreaks spread person-to-person, by animals or vectors or from an environmental, food or waterborne source of exposure; those that result from a deliberate act of terrorism; and unexplained deaths possibly due to unidentified infectious or chemical causes. | X | X | Detection in one or more specimens of etiological agents of a disease or condition not listed in this rule that is of urgent public health significance. This includes the identification of etiological agents that are suspected to be the cause of clusters, or outbreaks spread person-to-person, by animals or vectors or from an environmental, food, or waterborne source of exposure; those that result from a deliberate act of terrorism; and unexplained deaths due to unidentified infectious or chemical causes. | X | X | |||||||
Acquired Immune Deficiency Syndrome (AIDS) | 2 weeks | Acquired Immune Deficiency Syndrome (AIDS) | Laboratory Reporting Not Applicable | |||||||||
Amebic Encephalitis | X | Naegleria fowleri, Balamuthia mandrillaris, or Acanthamoeba species | X | |||||||||
Anthrax | X | X | Bacillus anthracis | X | X | X | ||||||
Antimicrobial resistance surveillance | Practitioner Reporting Not Applicable | Antimicrobial resistance surveillance (for organisms not otherwise listed in this table), Acinetobacter baumannii, Citrobacter species, Enterococcus species, Enterobacter species, Escherichia coli species, Klebsiella species, Pseudomonas aeruginosa, Serratia species, isolated from a normally sterile site *3 | X | |||||||||
Arsenic Poisoning *4a | X | Laboratory results as specified in the surveillance case definition *4a | X | |||||||||
Arboviral infections, not otherwise listed in this table (disease due to) *5 | X | Including but not limited to: Flaviviridae, Togaviridae (e.g. chikungunya, Western equine encephalitis), Bunyaviridae (e.g. Heartland, Rift Valley Fever) *5 | X | X | ||||||||
Babesiosis | X | Babesia spp. | X | X | ||||||||
Botulism, foodborne, other (includes wound and unspecified) | X | X | Clostridium botulinum or botulinum toxin | X | X | X | ||||||
Botulism, infant | X | Clostridium botulinum or botulinum toxin | X | X | ||||||||
Brucellosis | X | X | Brucella species | X | X | X | ||||||
California serogroup viruses (disease due to) | X | California serogroup viruses such as Jamestown Canyon, Keystone, and Lacrosse | X | X | ||||||||
Campylobacteriosis *4b | X | Campylobacter species *4b | X | |||||||||
Cancer (except non-melanoma skin cancer, and including benign and borderline intracranial and CNS tumors) *6 | 6 months | Pathological or tissue diagnosis of cancer (except non-melanoma skin cancer and including benign and borderline intracranial and CNS tumors) | 6 months | |||||||||
Carbon monoxide poisoning | X | A volume fraction >= 0.09 (9%) of carboxyhemoglobin in blood | X | |||||||||
CD-4 absolute count and percentage of total lymphocytes | Practitioner Reporting Not Applicable | CD-4 absolute count and percentage of total lymphocytes *7 | 3 days | |||||||||
Chancroid | X | Haemophilus ducreyi | X | |||||||||
Chlamydia *8 | X | Chlamydia trachomatis | X | |||||||||
Cholera | X | X | Vibrio cholerae | X | X | |||||||
Ciguatera fish poisoning | X | Ciguatera fish poisoning | Laboratory Reporting Not Applicable | |||||||||
Congenital anomalies *9 | 6 months | Congenital anomalies | Laboratory tests as specified in Rule 64D-3.035, F.A.C. | |||||||||
Conjunctivitis in neonates < 14 days old | X | Conjunctivitis in neonates < 14 days old | Laboratory Reporting Not Applicable | |||||||||
Coronavirus (COVID 19) *23 | X | Coronavirus (COVID 19) *23 | X | |||||||||
Creutzfeld-Jakob disease (CJD) *10 | X | 14-3-3 or tau protein detection in CSF or immunohistochemical test or any brain pathology suggestive of CJD *10 | X | |||||||||
Cryptosporidiosis *4b | X | Cryptosporidium species *4b | X | |||||||||
Cyclosporiasis | X | Cyclospora cayetanensis | X | X | ||||||||
Dengue *5 | X | Dengue virus *5 | X | X | ||||||||
Diphtheria | X | X | Corynebacterium diphtheriae | X | X | X | ||||||
Eastern equine encephalitis | X | Eastern equine encephalitis virus | X | X | ||||||||
Ehrlichiosis/Anaplasmosis | X | Anaplasma species or Ehrlichia species | X | X | ||||||||
Escherichia coli Shiga toxin-producing (disease due to) *4b | X | Escherichia coli Shiga toxin-producing *4b | X | X | ||||||||
Giardiasis (acute) *4b | X | Giardia species *4b | X | |||||||||
Glanders | X | X | Burkholderia mallei | X | X | X | ||||||
Gonorrhea *8 | X | Neisseria gonorrhoeae | X | |||||||||
Granuloma inguinale | X | Calymmatobacterium granulomatis | X | |||||||||
Haemophilus influenzae, meningitis and invasive disease, in children < 5 years old | X | X | Haemophilus influenzae, all ages, isolated from a normally sterile site *11 | X | X | X | ||||||
Hansen disease (Leprosy) | X | Mycobacterium leprae | X | |||||||||
Hantavirus infection | X | Hantavirus | X | X | ||||||||
Hemolytic uremic syndrome | X | Not Applicable | ||||||||||
Hepatitis A *4b, 12 | X | Hepatitis A*4b, 12 | X | |||||||||
Hepatitis B, C, D, E and G *12 | X | Hepatitis B, C, D, E and G Virus *12 | X | |||||||||
Hepatitis B surface antigen (HBsAg)-positive in a pregnant woman or a child up to 24 months old | X | Hepatitis B surface antigen (HBsAg) | X | |||||||||
Herpes B virus, possible exposure | X | Herpes B virus, possible exposure | Laboratory Reporting Not Applicable | |||||||||
Herpes simplex virus (HSV) in infants up to 60 days old with disseminated infection with involvement of liver, encephalitis and infections limited to skin, eyes and mouth *13 | X | HSV 1 or HSV 2 by direct FA, PCR, DNA or Culture *13 | X | |||||||||
HSV - anogenital in children < 12 years of age *8, 13 | X | HSV 1 or HSV 2 by direct FA, PCR, DNA or Culture *13 | X | |||||||||
Human immunodeficiency virus (HIV) infection | 2 weeks | Repeatedly reactive enzyme immunoassay, followed by a positive confirmatory tests, (e.g. Western Blot, IFA): Positive result on any HIV virologic test (e.g. p24 AG, Nucleic Acid Test (NAT/NAAT) or viral culture). All viral load (detectable and undetectable) test results.*14, 15 | 3 days | |||||||||
Human immunodeficiency virus (HIV) Exposed Newborn - infant < 18 months of age born to a HIV infected woman | X | All HIV test results (e.g., positive or negative immunoassay, positive or negative virologic tests) for those < 18 months of age | 3 days | |||||||||
Human papillomavirus (HPV) associated laryngeal papillomas or recurrent respiratory papillomatosis in children < 6 years of age *8 | X | HPV DNA | X | |||||||||
Human papillomavirus (HPV) - anogenital papillomas in children < 12 years of age *8 | X | HPV DNA | X | |||||||||
Human papillomavirus (HPV) | Practitioner Reporting Not Applicable | HPV DNA *3 | X | |||||||||
Influenza due to novel or pandemic strains | X | X | Isolation of influenza virus from humans of a novel or pandemic strain | X | X | X | ||||||
Influenza-associated pediatric mortality in persons aged < 18 years | X | Influenza virus - associated pediatric mortality in persons aged < 18 years (if known) | X | X | ||||||||
Influenza | Practitioner Reporting Not Applicable | Influenza virus, all test results (positive and negative) *3 | X | |||||||||
Lead poisoning *4, 16 | X | All blood lead test results (positive and negative) *3, 4, 16 | X | |||||||||
Legionellosis | X | Legionella species | X | |||||||||
Leptospirosis | X | Leptospira species | X | |||||||||
Listeriosis | X | Listeria monocytogenes | X | X | ||||||||
Lyme disease | X | Borrelia burgdorferi | X | |||||||||
Lymphogranuloma Venereum (LGV) | X | Chlamydia trachomatis | X | |||||||||
Malaria | X | Plasmodium species | X | X | ||||||||
Measles (Rubeola) | X | X | Measles virus *16 | X | X | X | ||||||
Melioidosis | X | X | Burkholderia pseudomallei | X | X | X | ||||||
Meningitis, bacterial or mycotic | X | Isolation or demonstration of any bacterial or fungal species in cerebrospinal fluid | X | |||||||||
Meningococcal disease | X | X | Neisseria meningitidis | X | X | |||||||
Mercury poisoning *4a | X | Laboratory results as specified in the surveillance case definition *4a | X | |||||||||
Mumps | X | Mumps virus | X | |||||||||
Neonatal Abstinence Syndrome *18 | 6 months | Neonatal Abstinence Syndrome | Laboratory Reporting Not Applicable | |||||||||
Neurotoxic shellfish poisoning | X | Laboratory results as specified in the surveillance case definition *4a | X | |||||||||
Pertussis | X | Bordetella pertussis | X | |||||||||
Pesticide-related illness and injury *4 | X | Laboratory results as specified in the surveillance case definition *4 | X | |||||||||
Plague | X | X | Yersinia pestis | X | X | X | ||||||
Poliomyelitis | X | X | Poliovirus | X | X | X | ||||||
Psittacosis (Ornithosis) | X | Chlamydophila psittaci | X | X | ||||||||
Q Fever | X | Coxiella burnetii | X | X | ||||||||
Rabies, animal or human | X | Rabies virus | X | X | ||||||||
Rabies, possible exposure *19 | X | X | Rabies, possible exposure | Laboratory Reporting Not Applicable | ||||||||
Respiratory syncytial virus | Practitioner Reporting Not Applicable | Respiratory syncytial virus, all test results (positive and negative) *3 | X | |||||||||
Ricin toxicity | X | X | Ricinine (from Ricinus communis castor beans) | X | X | X | ||||||
Rocky Mountain spotted fever and other Spotted Fever Rickettsioses | X | Rickettsia rickettsii and other Spotted Fever Rickettsia species | X | X | ||||||||
Rubella, including congenital | X | X | Rubella virus *17 | X | X | X | ||||||
St. Louis encephalitis (SLE) | X | St. Louis encephalitis virus | X | X | ||||||||
Salmonellosis *4b | X | Salmonella species *4b | X | X | ||||||||
Saxitoxin poisoning including Paralytic shellfish poisoning (PSP) | X | Saxitoxin | X | |||||||||
Severe acute respiratory disease syndrome-associated with a Coronavirus infection | X | X | Coronavirus associated with severe acute respiratory disease | X | X | X | ||||||
Shigellosis *4b | X | Shigella species *4b | X | |||||||||
Smallpox | X | X | Variola virus (orthopox virus) | X | X | X | ||||||
Staphylococcus aureus isolated from a normally sterile site | Practitioner Reporting Not Applicable | Staphylococcus aureus isolated from a normally sterile site *3 | X | |||||||||
Staphylococcus aureus with intermediate or full resistance to vancomycin (VISA, VRSA) | X | Staphylococcus aureus with intermediate or full resistance to vancomycin (VISA, VRSA); Laboratory results as specified in the surveillance case definition *4 | X | X | ||||||||
Staphylococcus enterotoxin B | X | Staphylococcus enterotoxin B | X | X | ||||||||
Streptococcus pneumoniae, invasive disease in children < 6 years, drug sensitive and resistant | X | Streptococcus pneumoniae, all ages, isolated from a normally sterile site *20 | X | |||||||||
Syphilis | X | Treponema pallidum | X | |||||||||
Syphilis in pregnant women and neonates | X | Treponema pallidum | X | |||||||||
Tetanus | X | Clostridium tetani | X | |||||||||
Trichinellosis (Trichinosis) | X | Trichinella spiralis | X | |||||||||
Tuberculosis (TB) *21 | X | Mycobacterium tuberculosis complex *21 | X | X | ||||||||
Tularemia | X | X | Francisella tularensis | X | X | X | ||||||
Typhoid fever and paratyphoid fever *4b | X | Salmonella enterica serotype Typhi and Salmonella enterica serotypes Paratyphi A, Paratyphi B, and Paratyphi C *4b | X | X | ||||||||
Typhus fever (epidemic) | X | X | Rickettsia prowazekii | X | X | X | ||||||
Vaccinia disease | X | X | Vaccinia virus | X | X | X | ||||||
Varicella (Chickenpox) *22 | X | Varicella virus | X | |||||||||
Varicella mortality | X | Varicella virus | X | |||||||||
Venezuelan equine encephalitis | X | X | Venezuelan equine encephalitis virus | X | X | X | ||||||
Vibriosis (infections by Vibrio species and closely related organisms, other than Cholera) | X | All non-cholera Vibrio species Photobacterium damselae, (formerly V. damsela); Grimontia hollisae (formerly V. hollisae) | X | X | ||||||||
Viral hemorrhagic fevers | X | X | Ebola, Marburg, Lassa, Machupo Lujo, new world Arena, or Congo-Crimean hemorrhagic fever viruses | X | X | X | ||||||
West Nile virus (disease due to) | X | West Nile virus | X | X | ||||||||
Yellow fever | X | X | Yellow fever virus | X | X | |||||||
Zika fever *5 | X | Zika fever virus *5 | X | X | ||||||||
*1 - Submission of isolates or specimens for confirmation to the Florida Department of Health, Bureau of Public Health Laboratories:
*2 - Include MIC (minimum inhibitory concentration), zone sizes for disk diffusion; MICs for E-test or agar dilution and interpretation (susceptible, intermediate, resistant).
*3 - Paper reports are not required. Applies only to laboratories performing electronic laboratory reporting as described in subsection 64D-3.031(5), F.A.C.
*4 - a. Surveillance Case Definitions for Select Reportable Diseases in Florida, 2016.
*5 - Report on suspicion of infection. Reports should occur without delay on initial suspicion but reports do not need to be made after-hours. Reports on initial suspicion are to allow for disease control measures to be immediately implemented (such as notification of mosquito control) in order to prevent local transmission.
*6 - Notification within six months of diagnosis and within six months of each treatment.
*7 - All CD-4 absolute count and percentage of total lymphocytes, with or without confirmed HIV infection.
*8 - Child abuse should be considered by a practitioner upon collection of a specimen for laboratory testing in any person 12 years of age or younger, excluding neonates. Reporting of a sexually transmissible disease (STD) case to a county health department does not relieve the practitioner of their mandatory reporting responsibilities regarding child abuse pursuant to Section 39.201, F.S.
*9 - Exceptions are located in Rule 64D-3.035, F.A.C.
*10 - Practitioners should contact the Department of Health, Bureau of Epidemiology at (850)245-4401 to arrange appropriate autopsy and specimen collection.
*11 - For Haemophilus influenza test results associated with persons older than 4 years of age, only electronic reporting is required, in accordance with subsection 64D-3.031(5), F.A.C.
*12 - Special reporting requirements for Hepatitis B (acute and chronic), C (acute and chronic), D, E, G: Positive results should be accompanied by any hepatitis testing conducted (positive and negative results); all serum aminotransferase levels, and if applicable, pregnancy test result or if testing is conducted as part of a pregnancy panel. For laboratories performing electronic laboratory reporting as described in subsection 64D-3.031(5), F.A.C., all test results performed (positive and negative) are to be submitted, including screening test results (positive and negative).
*13 - A 4-fold titer rise in paired sera by various serological tests confirmatory of primary infection; presence of herpes-specific IgM suggestive but not conclusive evidence of primary infection.
*14 - Special requirements for STARHS (Serologic Testing Algorithm for Recent HIV Seroconversion):
*15 - Laboratories shall submit a genotype for each confirmed positive HIV specimen on a fasta file containing the nucleotide sequence data, including the protease and reverse transcriptase regions.
*16 - Special reporting requirements for reporting blood lead tests:
*17 - IgM serum antibody or viral culture test orders for measles (rubeola) or rubella should be reported as suspect immediately, but not IgG orders or results.
*18 - Each hospital licensed under Chapter 395, F.S., shall report each case of neonatal abstinence syndrome occurring in an infant admitted to the hospital. If a hospital reports a case of neonatal abstinence syndrome to the Agency for Health Care Administration in its inpatient discharge data report, pursuant to Chapter 59E-7, F.A.C., then it need not comply with the reporting requirements of subsection 64D-3.029(1), F.A.C.
*19 - Exposure to Rabies, as defined in Rule 64D-3.028, F.A.C., that results in rabies prophylaxis for the person exposed, rabies testing, isolation or quarantine of the animal causing the exposure.
*20 - For Streptococcus pneumonia test results associated with persons older than 5 years, only electronic reporting is required, in accordance with subsection 64D-3.031(5), F.A.C.
*21 - Test results must be submitted by laboratories to the Department of Health, Tuberculosis Control Section, 4052 Bald Cypress Way, Bin A20, Tallahassee, Florida 32399-1717, (850)245-4350.
*22 - Practitioners shall also provide dates of varicella vaccination.
*23- Special reporting requirements for COVID-19:
Fla. Admin. Code Ann. R. 64D-3.029
Rulemaking Authority 381.0011(2), 381.003(2), 381.0031(8), 384.33, 392.53(2), 392.66 FS. Law Implemented 381.0011(3), (4), 381.003(1), 381.0031(2), (4), (5), (6), (8), 383.06, 384.25, 385.202, 392.53 FS.
New 11-20-06, Amended 11-24-08, 6-4-14, 10-20-16, 8-18-21.